Latest & greatest articles for amlodipine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amlodipine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amlodipine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amlodipine

41. Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA

Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA Rossetti F, De Portu S, Menditto E, Scalone L, Bustacchini S, Cricelli C, Mantovani L G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The administration of amlodipine besylate therapy to patients undergoing percutaneous transluminal coronary angioplasty (PTCA) was studied. The patients were given 5 mg amlodipine besylate once daily during the first week after randomisation, which occurred 2 weeks before the PTCA. After that they were given 10 mg once daily

2006 NHS Economic Evaluation Database.

42. The pharmacoeconomic impact of amlodipine use on coronary artery disease

The pharmacoeconomic impact of amlodipine use on coronary artery disease The pharmacoeconomic impact of amlodipine use on coronary artery disease The pharmacoeconomic impact of amlodipine use on coronary artery disease De Portu S, Menditto E, Scalone L, Bustacchini S, Cricelli C, Mantovani L G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined standard care supplemented by amlodipine besylate (AB) for patients with coronary artery disease (CAD). Type of intervention Secondary prevention. Economic study type Cost effectiveness analysis. Study population The study population was a hypothetical cohort of persons with angiographically documented CAD. Setting The setting was unclear. The economic study

2006 NHS Economic Evaluation Database.

43. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B (PubMed)

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics and beta blockers used. For a given reduction in blood pressure, some suggested (...) that newer agents would confer advantages over diuretics and beta blockers. Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril.We did a multicentre, prospective, randomised controlled trial in 19 257 patients with hypertension who were aged 40-79 years and had at least three other cardiovascular risk factors. Patients were assigned either amlodipine 5-10 mg adding perindopril 4-8 mg

2005 Lancet

44. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. (PubMed)

Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. Few cardiovascular outcome data are available for blacks with hypertension treated with angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs).To determine whether an ACE inhibitor or CCB is superior to a thiazide-type diuretic in reducing cardiovascular disease (CVD) incidence in racial subgroups.Prespecified subgroup analysis of ALLHAT, a randomized, double (...) -blind, active-controlled, clinical outcome trial conducted between February 1994 and March 2002 in 33,357 hypertensive US and Canadian patients aged 55 years or older (35% black) with at least 1 other cardiovascular risk factor.Antihypertensive regimens initiated with a CCB (amlodipine) or an ACE inhibitor (lisinopril) vs a thiazide-type diuretic (chlorthalidone). Other medications were added to achieve goal blood pressures (BPs) less than 140/90 mm Hg.The primary outcome was combined fatal coronary

Full Text available with Trip Pro

2005 JAMA

45. Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension

Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension Article Text Therapeutics Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD

Full Text available with Trip Pro

2004 Evidence-Based Medicine (Requires free registration)

46. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. (PubMed)

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk.15?245 patients, aged 50 years or older with treated or untreated (...) hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4.2 years.Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were

2004 Lancet

47. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. (PubMed)

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. Many patients with chronic angina experience anginal episodes despite revascularization and antianginal medications. In a previous trial, antianginal monotherapy with ranolazine, a drug believed to partially inhibit fatty acid oxidation, increased treadmill exercise performance; however, its long-term efficacy and safety (...) have not been studied in combination with beta-blockers or calcium antagonists in a large patient population with severe chronic angina.To determine whether, at trough levels, ranolazine improves the total exercise time of patients who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem and to determine times to angina onset and to electrocardiographic evidence of myocardial ischemia, effect

Full Text available with Trip Pro

2004 JAMA

48. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria

Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Smith D G, Nguyen A B, Peak C N (...) (Diovan) and the calcium-channel blocker amlodipine (Norvasc). Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients with Type 2 diabetes and microalbuminuria. The characteristics of the target population were not described in full detail. The reader is referred to the original clinical study, the MicroAlbuminuria Reduction with VALsartan (MARVAL) study (see 'Other Publications of Related Interest' below for bibliographic

2004 NHS Economic Evaluation Database.

49. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada

Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada Coyle D, Rodby R A Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Irbesartan (an angiotensin-II-receptor antagonist) was compared with amlodipine (a calcium-channel blocker) and standard care for the treatment of patients with Type 2 diabetes, with hypertension and proteinuria. Standard care concerned

2004 NHS Economic Evaluation Database.

50. Effect of amlodipine on systolic blood pressure

Effect of amlodipine on systolic blood pressure Effect of amlodipine on systolic blood pressure Effect of amlodipine on systolic blood pressure Levine C B, Fahrbach K R, Frame D, Connelly J E, Estok R P, Stone L R, Ludensky V CRD summary This manufacturer-funded review concluded that amlodipine given alone is effective for reducing systolic blood pressure in people with hypertension. The conclusions should be treated with caution because of methodological and reporting limitations in the review (...) . Authors' objectives To examine the effectiveness of amlodipine in lowering systolic blood-pressure (SBP). Searching MEDLINE was searched from January 1980 to June 2001. The search terms were 'Amlodipine' and 'Norvasc'. Current Contents (Clinical Medicine) and the Cochrane Library were also searched. The reference lists from all accepted studies and recent reviews were checked. Abstracts, letters, comments and reviews were excluded, as was articles written in languages other than English, French German

2003 DARE.

51. Evaluation of a therapeutic conversion from amlodipine to felodipine

Evaluation of a therapeutic conversion from amlodipine to felodipine Evaluation of a therapeutic conversion from amlodipine to felodipine Evaluation of a therapeutic conversion from amlodipine to felodipine Manzo B A, Matalka M S, Ravnan S L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The study examined the effectiveness of felodipine compared with amlodipine in elderly hypertensive patients, after switching treatment with amlodipine (10 mg) to felodipine (10 mg). The patients were converted from amlodipine on an identical milligram dose of felodipine. Dosage adjustments after the conversion were left to the discretion of primary care providers. Type of intervention Treatment. Economic study type Cost-effectiveness

2003 NHS Economic Evaluation Database.

52. A comparative analysis of amlodipine and felodipine in a military outpatient population: efficacy, outcomes, and cost considerations

A comparative analysis of amlodipine and felodipine in a military outpatient population: efficacy, outcomes, and cost considerations A comparative analysis of amlodipine and felodipine in a military outpatient population: efficacy, outcomes, and cost considerations A comparative analysis of amlodipine and felodipine in a military outpatient population: efficacy, outcomes, and cost considerations Blivin S J, Pippins J, Annis L G, Lyons F Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of amlodipine (AML) and felodipine (FEL), two dihydropyridine calcium-channel blockers, for the treatment of hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study

2003 NHS Economic Evaluation Database.

53. A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden

A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden Doyle J J, McGuire A, Arocho R, Arikian S, Casciano J, Svangren P, Casciano R, Kim R, Kugel H Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of amlodipine (10 mg/day), for the prevention of atherosclerosis in patients with coronary artery disease (CAD). Type of intervention Secondary prevention. Economic study type Cost-effectiveness study. Study population The study population comprised a hypothetical cohort

2002 NHS Economic Evaluation Database.

54. Amlodipine treatment in patients undergoing PTCA in the UK: a cost-effectiveness analysis

Amlodipine treatment in patients undergoing PTCA in the UK: a cost-effectiveness analysis Amlodipine treatment in patients undergoing PTCA in the UK: a cost-effectiveness analysis Amlodipine treatment in patients undergoing PTCA in the UK: a cost-effectiveness analysis Doyle J J, Thaulov E, Jorgensen B, Casciano R, Casciano J, Kopp Z, Marchant N, Kim R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of amlodipine after percutaneous transluminal coronary angioplasty (PTCA), from 2 weeks prior to PTCA until 4 months after the intervention. The dose used was 5 mg during the first week and 10 mg thereafter. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population

2002 NHS Economic Evaluation Database.

55. The economic efficiency of amlodipine in the treatment of coronary atherosclerosis: an analysis based on the PREVENT study

The economic efficiency of amlodipine in the treatment of coronary atherosclerosis: an analysis based on the PREVENT study The economic efficiency of amlodipine in the treatment of coronary atherosclerosis: an analysis based on the PREVENT study The economic efficiency of amlodipine in the treatment of coronary atherosclerosis: an analysis based on the PREVENT study Cathomas G, Erne P, Schwenkglenks M, Szucs T D Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of the calcium antagonist amlodipine (initially 5 mg/day, then 10 mg/day) in patients with coronary atherosclerosis. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised

2002 NHS Economic Evaluation Database.

56. Economic benefits of amlodipine treatment in patients with coronary artery disease

Economic benefits of amlodipine treatment in patients with coronary artery disease Economic benefits of amlodipine treatment in patients with coronary artery disease Economic benefits of amlodipine treatment in patients with coronary artery disease Casciano R, Doyle J J, Chen J, Arikian S, Casciano J, Kugel H, Arocho R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of amlodipine for the treatment of patients with coronary artery disease (CAD). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised the general population of patients with CAD. Setting The setting was primary care. The economic study was carried out in USA. Dates

2002 NHS Economic Evaluation Database.

57. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. (PubMed)

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. Incidence of end-stage renal disease due to hypertension has increased in recent decades, but the optimal strategy for treatment of hypertension to prevent renal failure is unknown, especially among African Americans.To compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine), and a beta-blocker (...) (metoprolol) on hypertensive renal disease progression.Interim analysis of a randomized, double-blind, 3 x 2 factorial trial conducted in 1094 African Americans aged 18 to 70 years with hypertensive renal disease (glomerular filtration rate [GFR] of 20-65 mL/min per 1.73 m(2)) enrolled between February 1995 and September 1998. This report compares the ramipril and amlodipine groups following discontinuation of the amlodipine intervention in September 2000.Participants were randomly assigned to receive

2001 JAMA

58. Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers

Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers Parra D, Beckey N P, Korman L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) collected retrospectively using the same population sample as that used in the effectiveness analysis. Study sample 314 patients who had undergone conversion from amlodipine to other calcium channel blockers were identified. The method of sample selection and randomisation to identify this group were not stated in the paper. 212 (67.5%) of these patients did not meet the study protocol criteria and were excluded from the analysis. Another two patients (0.6%) appear to have been excluded although

2000 NHS Economic Evaluation Database.

59. A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension

A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension Whitcomb C, Enzmann G, Pershadsingh H A, Johnson R, Ciuryla V, Reisin E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two long-acting dihydropyridine calcium antagonists, amlodipine and nisoldipine extended-release, for the treatment of mild to moderate hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised adult patients with Stage I

2000 NHS Economic Evaluation Database.

60. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. (PubMed)

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. Previous studies have shown that calcium-channel blockers increase morbidity and mortality in patients with chronic heart failure. We studied the effect of a new calcium-channel blocker, amlodipine, in patients with severe chronic heart failure.We randomly assigned 1153 patients with severe chronic heart failure and ejection fractions of less than (...) 30 percent to double-blind treatment with either placebo (582 patients) or amlodipine (571 patients) for 6 to 33 months, while their usual therapy was continued. The randomization was stratified on the basis of whether patients had ischemic or nonischemic causes of heart failure. The primary end point of the study was death from any cause and hospitalization for major cardiovascular events.Primary end points were reached in 42 percent of the placebo group and 39 percent of the amlodipine group

1996 NEJM